Spindle proteins are differentially expressed in the various histological subtypes of testicular germ cell tumors.
BACKGROUND
Testicular germ cell tumors (TGCTs) are characterized by an aneuploid DNA content. Aberrant expression of spindle proteins such as the Aurora kinases and the spindle checkpoint proteins MAD2 and BUB1B, are thought to contribute to the development of chromosomal instability and DNA aneuploidy in cancer. The importance of these spindle proteins remains unknown in the development of TGCTs, thus we have explored the expression levels of these proteins in normal and malignant testicular tissues.


METHODS
Using tissue microarrays the expression levels of Aurora kinase A (AURKA), Aurora kinase B (AURKB), BUB1B and MAD2 were measured in normal, preneoplastic and malignant testicular tissues of different histological subtypes from 279 orchidectomy specimens by means of immunohistochemistry.


RESULTS
All the spindle proteins except for AURKB were expressed in normal testis. Sixty-eight and 36%, respectively, of the primary spermatocytes in the normal testis were positive for BUB1B and MAD2, while only 5% of the cells were positive for AURKA. There was a significantly lower expression of the spindle checkpoint proteins in carcinoma in situ compared to normal testis (P=0.008 and P=0.043 for BUB1B and MAD2, respectively), while the level of AURKA was increased, however, not significantly (P=0.18). The extent of spindle protein expression varied significantly within the different histological subtypes of TGCTs (P<0.001 for AURKB, BUB1B and MAD2, P=0.003 for AURKA). The expression of AURKA was significantly elevated in both non-seminomas (P=0.003) and seminomas (P=0.015). The level of BUB1B was significantly decreased in non-seminomas (P<0.001). A similar tendency was observed for MAD2 (P=0.11).


CONCLUSIONS
In carcinoma in situ of TGCTs the spindle checkpoint proteins MAD2 and BUB1B are significantly less expressed compared to normal testis, while the expression of AURKA is increased. We suggest that these changes may be of importance in the transition from in situ to invasive testicular cancer.
Burum-Auensen
Espen
E
Division of Pathology, Medical Faculty, University of Oslo, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Skotheim
Rolf I
RI
Schjølberg
Aasa R
AR
Røislien
Jo
J
Lothe
Ragnhild A
RA
Clausen
Ole Petter F
OP
J Neurooncol. 2004 Mar-Apr;67(1-2):53-64
15072448
Cancer Cell. 2003 Jan;3(1):51-62
12559175
Cancer Treat Rev. 2008 Apr;34(2):175-82
18023292
Virchows Arch A Pathol Anat Histol. 1982 Aug;396(3):247-77
6291228
Cancer Lett. 2006 Aug 8;239(2):234-8
16182441
Clin Cancer Res. 2005 Mar 1;11(5):1827-34
15756006
J Biol Chem. 2002 Feb 15;277(7):5187-93
11729202
Oncogene. 2003 Jan 9;22(1):109-16
12527913
Trends Cell Biol. 1999 Nov;9(11):454-9
10511710
Cancer Res. 2003 Mar 15;63(6):1398-404
12649205
Nat Genet. 2004 Nov;36(11):1159-61
15475955
Cancer Genet Cytogenet. 2007 Apr 1;174(1):42-7
17350465
Oncogene. 2003 Jun 19;22(25):3859-66
12813459
Nat Rev Cancer. 2001 Nov;1(2):109-17
11905802
Clin Cancer Res. 2003 Apr;9(4):1420-6
12684414
Br J Cancer. 2006 Aug 21;95(4):475-84
16880791
APMIS. 2003 Jan;111(1):267-78; discussion 278-9
12752272
J Clin Endocrinol Metab. 2005 Feb;90(2):928-35
15562011
Biochim Biophys Acta. 2007 Jun;1773(6):821-32
17467818
Lab Invest. 1992 Feb;66(2):166-8
1310514
Curr Opin Cell Biol. 2002 Dec;14(6):706-14
12473343
Int J Biochem Cell Biol. 2005 Dec;37(12):2437-56
16099193
Cancer Res. 2006 Apr 15;66(8):4357-67
16618761
Cancer Res. 2003 Jun 1;63(11):2855-63
12782591
Cell Prolif. 2008 Aug;41(4):645-59
18699967
J Histochem Cytochem. 2007 May;55(5):477-86
17242465
Anticancer Res. 1999 Nov-Dec;19(6A):4887-906
10697602
Oncogene. 2006 Jun 15;25(25):3598-605
16449973
Curr Opin Genet Dev. 1999 Feb;9(1):69-75
10072359
APMIS. 2003 Jan;111(1):136-50; discussion 50-1
12752254
Nat Genet. 2004 Jul;36(7):744-9
15208629
Trends Cell Biol. 2005 May;15(5):241-50
15866028
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1518-22
14693746
Urol Res. 2003 Dec;31(6):382-6
13680024
J Endocrinol. 2004 May;181(2):263-70
15128274
J Biol Chem. 2004 Nov 5;279(45):47201-11
15316025
J Clin Pathol. 2007 Dec;60(12):1403-8
17322345
Neoplasia. 2003 Sep-Oct;5(5):397-404
14670177
Nat Genet. 1998 Oct;20(2):189-93
9771714
J Cell Biol. 2003 Apr 28;161(2):281-94
12707311
Mol Cell Biol. 2002 Feb;22(3):874-85
11784863
Cancer Genet Cytogenet. 2000 Jun;119(2):83-93
10867141
EMBO J. 1998 Jun 1;17(11):3052-65
9606188